Genmab jumps 28% as its head and neck cancer drug halves the risk of death
Why is Genmab stock up today?
Genmab said its experimental drug petosemtamab, given with Merck's Keytruda, cut the risk of death by half compared with Keytruda alone in a Phase 3 trial in advanced head and neck cancer, as a first drug treatment. The result came at a first interim analysis, and full data aren't out yet. The shares closed up 28%. Bicara and Inhibrx, which are testing rival drugs with Keytruda in the same disease, fell 44% and 23%.
- Move
- ▲ 28.3%
- Price
- $44.67 → $57.29
- Value gained
- ~$7.8B
- Risk of death
- −50% (HR 0.50)
- Patients in trial
- 699
- Bicara same day
- ▼ 44%
Prices: closing price, Oct 28, 2026 · Company data: 20-F, Dec 31, 2025 · What these numbers mean
Closing prices of Genmab's US-listed ADSs (10 ADSs = 1 share) on Oct 28, 2026 (Nasdaq); the day's range was $44.35–59.97. Genmab's Copenhagen shares closed up 29.1% (Yahoo Finance). Market value change uses Yahoo's ~615 million ADS-equivalent shares.
Snapshot at the Oct 28, 2026 close
- Market value
- $35.3B
- Enterprise value
- $38.9B
- Price/sales
- 9.5×
- EV/sales
- 10.4×
- P/E
- 36.7×
- Price/FCF
- 31.2×
- Revenue growth
- +19%
- FCF margin
- 30%
- Net debt
- $3.6B
Our calculation from the company's filings (latest: 20-F for the fiscal year to Dec 31, 2025); not investment advice. Revenue, earnings and cash flow: FY2025 (year to Dec 31, 2025). Price $57.29. n/m = not meaningful (e.g. negative earnings).
What happened
Genmab reported that its experimental drug improved survival in a large, late-stage trial in head and neck cancer, and its shares jumped.
- On Wednesday morning, Genmab said its Phase 3 LiGeR-HN1 trial met both of its main goals, overall survival and tumor response rate, at its first interim analysis. These are headline (topline) results; the detailed data come later.
- The trial enrolled 699 patients with head and neck cancer that had come back or spread, who had not yet had drug treatment for that advanced stage (first-line), and whose tumors carry the immune marker PD-L1 (ClinicalTrials.gov). Patients got Keytruda, Merck’s immunotherapy and the standard option here, either with or without petosemtamab.
- Adding petosemtamab cut the risk of death by 50%, regardless of whether the cancer was linked to human papillomavirus (HPV), Genmab said. An independent data monitoring committee ran the analysis; Genmab reported no new safety signals.
- Genmab’s US-listed shares rose 16.8% in morning trading (Investing.com, 9:57 a.m. ET) and closed up 28.3% at $57.29 (Nasdaq). The S&P 500 and the Nasdaq Composite both rose 0.3%, and the SPDR S&P Biotech ETF (XBI) 1.7% (S&P 500: Yahoo Finance; Nasdaq Composite and XBI: Nasdaq).
It was Genmab’s second positive Phase 3 result in a week: on Oct 23, its drug Rina-S improved survival in ovarian cancer that no longer responds to platinum chemotherapy.
The result
Genmab has released only the headline statistics so far. Both were highly statistically significant.
| Measure | Result | What it means |
|---|---|---|
| Overall survival | Hazard ratio 0.50 (95% CI 0.37–0.67) | Half the risk of death at any given time during follow-up |
| Objective response | Odds ratio 3.17 (95% CI 2.06–4.89) | Odds of tumor shrinkage about 3 times higher |
Source: Genmab, Oct 28. The confidence intervals (CI) show the uncertainty around each estimate. The response figure compares odds of tumor shrinkage, not response percentages; Genmab has not yet released the survival times or response rates in each group.
According to Genmab, petosemtamab binds two proteins on tumor cells: EGFR, a receptor involved in cell growth, and LGR5, found on some stem-like cancer cells linked to relapse. It also helps immune cells kill the tumor. The approved head and neck cancer drug cetuximab (Erbitux) also blocks EGFR. Genmab got the drug through its roughly $8 billion purchase of Merus, agreed in September 2025.
Why the market reacted this way
Three features of the result stand out:
- The main goal met was overall survival, not only tumor shrinkage.
- It came at the first interim analysis, not the final one.
- The comparison was against Keytruda alone, the standard first treatment for these patients, and the combination uses no chemotherapy. Genmab’s release quotes Everett Vokes of University of Chicago Medicine calling it “the first positive Phase 3 study in this patient population in several years.”
The new trial’s survival times haven’t been released. Earlier, in a small single-group Phase 2 study of the same combination, the 43 patients evaluated lived a median 28.2 months (Genmab, presented at ESMO on Oct 26). That study had no comparison group and a different setup, so it can’t show the size of the benefit in the Phase 3 trial.
Analysts quoted by BioSpace were upbeat. William Blair called the result “exceedingly positive.” Truist Securities called it potentially practice-changing and said it suggests approval could come in 2027, a year earlier than it had modeled; Truist estimates median survival of about 30 months with the combination, an estimate, not company data.
Bicara and Inhibrx
Two smaller companies with rival drugs fell sharply: Bicara closed down 44.2% and Inhibrx down 23.4% (Nasdaq). Neither filed anything with the SEC on Wednesday, and StockTitan found no company news for either as of 12:01 p.m. ET.
- Bicara (BCAX) is testing ficerafusp alfa with Keytruda in FORTIFI-HN01, a Phase 2/3 trial in first-line, PD-L1-positive head and neck cancer; throat (oropharynx) cancers must be HPV-negative (ClinicalTrials.gov). The drug targets EGFR and blocks TGF-β, a signal that can suppress the immune response around tumors, according to Bicara.
- Inhibrx (INBX) is testing ordastobart (INBRX-106) with Keytruda in HexAgon-HN, a Phase 2/3 trial in a subgroup: first-line, HPV-positive throat (oropharynx) cancer (ClinicalTrials.gov).
BioSpace, reporting on Genmab’s result, described Bicara’s drug as a potential competitor and noted its share drop. Not every analyst read it as bad news for Bicara: BMO Capital Markets said the early survival result increased its confidence that ficerafusp can show a survival benefit at its mid-2027 Phase 3 interim analysis (BioSpace). Our interpretation is that Genmab’s result could raise the competitive bar for these programs; we have not verified that this explains their declines.
Does this change Genmab’s future?
What did NOT change
Petosemtamab is still experimental. These are interim, headline results, and the full data, including survival times and side-effect details, have yet to be presented. Genmab’s release gave no filing date.
What DID change
Genmab now has a late-stage drug with survival data in a first-line setting, which matters because its current income is concentrated. “The substantial majority of our revenue comes from royalties on sales of DARZALEX,” Johnson & Johnson’s myeloma drug, Genmab says in its annual report. Assuming unchanged underlying Darzalex sales, it expects those royalties to begin declining materially in 2029 as its US patent rights expire. Petosemtamab is also in Phase 3 trials in later-line head and neck cancer and in colorectal cancer.
Our read
If the full data hold up, this is a long-term change for Genmab, not a one-day story: petosemtamab now has Phase 3 survival data to take to regulators. The open questions are the actual survival gain, side effects, and how fast Genmab can launch before its Darzalex royalties start to fall.
What to watch next
- To be announced
- Full LiGeR-HN1 results at a medical meeting, including the actual survival times and response rates, which Genmab has not yet released.
- Not yet announced
- Talks with regulators and a filing date, which the release did not give. When it agreed to buy Merus in 2025, Genmab said a first launch of petosemtamab could come in 2027, subject to results and approvals.
- Nov 5
- Genmab publishes its results for the first nine months of 2026, after 5 p.m. CET, according to its financial calendar.
Quick questions
Is petosemtamab approved?
No. It is experimental. Genmab plans to discuss the results with regulators and has not announced a filing date.
Does a hazard ratio of 0.50 mean patients lived twice as long?
No. It means the estimated rate of death during follow-up so far was about half that in the Keytruda-only group. It does not show that patients lived twice as long; Genmab hasn't yet released how long patients lived in each group.
Why did Bicara and Inhibrx fall?
Neither filed anything with the SEC on Wednesday, and StockTitan found no company news for either as of midday. BioSpace described Bicara's drug as a potential competitor. Both are testing drugs with Keytruda as a first drug treatment for advanced head and neck cancer. Our interpretation is that Genmab's result could raise the competitive bar for them; we have not verified that this explains their declines.
Is this the final result?
No. It is a first interim analysis by an independent monitoring committee. The trial continues, and full results will be presented at a future medical meeting.
About Genmab: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
+ 9 more
Accessed Oct 28, 2026: Genmab: Rina-S RAINFOL-02 topline results (SEC 6-K), Oct 23 · Genmab: updated Phase 2 head and neck data (ESMO), Oct 26 (via Yahoo Finance) · Genmab: agreement to acquire Merus (SEC 6-K), Sep 29, 2025 · Genmab: 2025 annual report (SEC 20-F), Darzalex royalties · ClinicalTrials.gov: Bicara FORTIFI-HN01 (NCT06788990) · ClinicalTrials.gov: Inhibrx HexAgon-HN (NCT06295731) · Investing.com: why Genmab stock is surging, Oct 28 (9:57 a.m.) · BioSpace: Genmab's early OS win (analyst views), Oct 28 · Nasdaq: GMAB, BCAX and INBX closing quotes, Oct 28
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.